Product image of Lenalidomide Accord (Lenalidomide) supplied by GNH India

Lenalidomide Accord

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Accord (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Accord, is an immunomodulatory drug presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes, particularly in adult patients who have received prior therapy.

GNH India supplies Lenalidomide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell proliferation or dysplastic bone‑marrow clones.

  • Multiple Myeloma: improves progression‑free survival and reduces tumor burden in patients with relapsed or refractory disease.
  • Myelodysplastic Syndromes (deletion 5q): decreases transfusion dependence and improves hematologic parameters in eligible patients.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, prompting selective degradation of the transcription factors Ikaros and Aiolos. This action modulates the immune system, inhibits angiogenesis, and exerts direct anti‑myeloma activity, thereby reducing malignant plasma‑cell growth and improving bone‑marrow function.

Side Effects

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Neutropenia: reduced white blood cell count increasing infection risk.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: upset stomach often occurring after dosing.
  • Diarrhea: loose stools that may lead to dehydration.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs requiring immediate attention.
  • Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Secondary primary malignancies: emergence of new cancers during treatment.

Precautions & Warnings

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risks.

  • Pregnancy contraindication: Category X; avoid use in pregnant women and ensure effective contraception.
  • Thrombotic risk: assess patient history and consider prophylactic anticoagulation.
  • Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
  • Renal impairment: adjust dose in patients with reduced kidney function.
  • Drug interaction vigilance: review concomitant medications for CYP3A4 modulators.
  • Store below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Lenalidomide interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Thalidomide: combined use increases teratogenic and neuropathic risk.
  • Strong CYP3A4 inducers (e.g., rifampin): markedly lower lenalidomide plasma levels.
  • Anticoagulants (e.g., warfarin): may enhance bleeding tendency.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole): can raise lenalidomide exposure.
  • NSAIDs: may exacerbate neutropenia or gastrointestinal irritation.
  • Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.

Frequently Asked Questions

Lenalidomide Accord contains the active ingredient lenalidomide, an immunomodulatory drug indicated for the treatment of adult patients with multiple myeloma, particularly those who have received prior therapy, and for myelodysplastic syndromes that feature a deletion of chromosome 5q. It works by targeting abnormal plasma cells and dysplastic bone‑marrow clones.

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors Ikaros and Aiolos. This results in modulation of the immune response, inhibition of angiogenesis, and direct anti‑myeloma activity, reducing tumor growth and improving blood‑cell production.

The specific dose and schedule of Lenalidomide Accord are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Healthcare providers tailor the regimen to achieve optimal efficacy while monitoring safety parameters.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide generally offers greater potency, a more favorable safety profile, and reduced risk of peripheral neuropathy. Lenalidomide also has distinct pharmacokinetic properties and is often preferred for multiple myeloma and certain myelodysplastic syndromes.

Lenalidomide Accord should be stored at temperatures not exceeding 25 °C, in a dry place away from direct sunlight. Keep the product in its original container, tightly closed, and protect it from moisture to maintain stability.

Lenalidomide Accord is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow the dosing schedule provided by their healthcare professional.

The most serious risks include venous thromboembolism, severe skin reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and profound cytopenias that can lead to infection or bleeding. Prompt medical attention is required if any of these events occur.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with uncontrolled thrombotic disorders, or those lacking appropriate contraceptive measures. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT